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diagnosis. The newly applied chemotherapeutic agents in combination 
with radiotherapy shows improved response rate and survival. This 
study aimed to compare the effects of concurrent radiation and weekly 
cisplatin doublets with paclitaxel, or docetaxel, or gemcitabine.
Methods: Main eligibility criteria consisted of previously untreated 
stage IIIB NSCLC, age 18-75 years, PS ≤ 2, weight loss < 5%. After 
the informed consent, patients were randomized according to histology 
and institution. Since March 2005, eligible patients were randomized 
into three arms: paclitaxel 45mg/m2/week(TP), docetaxel 20mg/m2/
week(DP), gemcitabine 350mg/m2/week(GP) in addition to cisplatin 
20mg/m2/week. Three-dimensional conformal radiotherapy (3DCRT) 
was given once daily, 2-2.4Gy fraction to the GTV, weekly 5 fractions 
and the total prescription dose was over 60 Gy. Chemotherapy was 
initiated concurrently with the ﬁrst date of radiotherapy and repeated 
weekly for the following 6 weeks. Four weeks after the completion of 
CCRT, we proceeded to the three weekly consolidation chemotherapy: 
Paclitaxel 150mg/m2, docetaxel 75mg/m2, gemcitabine 1250mg/m2 
with cisplatin 60mg/m2. The primary end-point was response rate and 
the secondary end-points were survival and toxicity. Tumor response 
was measured on the basis of CT and/or PET-CT imaging using WHO 
criteria. Toxicities were evaluated by RTOG and NCI-CTC criteria.
Results: This trial is on-going at the present time. For this preliminary 
analysis, we included the ﬁfty-one patients (TP: 19, DP: 14, GP: 18) 
who completed the CCRT by October 2006. Similar overall response 
rates are observed; TP: 94.7%, GP: 92.9%, DP: 94.4%, respectively 
(p=1.0). There is no signiﬁcant difference in median survival; TP: not 
reached, GP: 13 months, DP: not reached (p=0.31). Radiation esopha-
gitis (≥grade 2) was noted in 5%(TP), 3%(DP), and 8%(GP, p=0.673) 
and radiation pneumonitis(≥grade 2) was observed in 2%(TP), 0%(DP), 
and 6%(GP, p=0.017). During the CCRT, both hematologic (p=0.31) 
and non-hematologic toxicities (p=0.27) were not different in three 
arms.
Conclusions: Among the 3 arms, no signiﬁcant difference in response 
rate and survival is observed. Tendency of different toxicity proﬁles are 
being observed.
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Background: The combination of chemotherapy and thoracic radiation 
is considered the standard treatment for locally advanced non-small 
cell lung cancer (NSCLC). However, the most favorable chemotherapy 
regime, timing of full-dose chemotherapy and the best way to combine 
chemotherapy with radiation to maximize systemic and radiosensitizing 
effects remains to be determined. The primary objective of this study 
was to evaluate the efﬁcacy and safety as well as tolerability of gem-
citabine with concurrent radiotherapy for locally advanced NSCLC.
Patients and Methods: Seventeen patients with histologically proven 
stage IIIA and IIIB NSCLC with no concurrent diseases and ECOG 
performance status 0-2 were included. Carboplatin was administered at 
an AUC of 2.5 and gemcitabine at 800mg/m2. Both drugs were given 
on day 1 and 8, every 21 days for two cycles, followed by conventional 
fractioned thoracic radiotherapy up to 60 Gy and concomitant weekly 
gemcitabine 200mg, followed by another 4 chemotherapy cycles post 
radiotherapy. 
Results: Ten patients (63%) had stage IIIB disease. Partial response 
was observed in 9 patients (57.1%) following induction chemotherapy. 
The most common hematological side effects were anemia (15.8%) 
neutropenia (15.8%) and thrombocytopenia (15.8%). Ten per cent 
experienced grade 3/4 emesis after the chemotherapy was given. After 
concurrent chemo-radiotherapy, global response was 66.7%, and 
grade 3/4 pneumonitis and anemia was observed in 28.6 and 15.8% 
respectively. Four patients (23%) underwent surgical resection. One 
treatment-related death from radiation pneumonitis occurred. Median 
progression-free survival was 18 ± 8.3 months. 
Conclusion: Induction chemotherapy with gemcitabine and carboplatin 
followed by concurrent chemoradiotherapy with gemcitabine followed 
by consolidation chemotherapy showed a response rate that is par-
ticularly noteworthy, considering the advanced stage and its favorable 
tolerability proﬁle.
P2-162 NSCLC: Combined Modality Therapy Posters, Tue, Sept 4 
Phase I trial of gefitinib in combination with concurrent 
carboplatin, paclitaxel and radiation therapy in patients with stage 
III non small cell lung cancer (“CRITICAL”)
Ball, David1 Burmeister, Bryan2 Mitchell, Paul3 Boyer, Michael4 Mac 
Manus, Michael1 Walpole, Euan2 Feigen, Malcolm3 Tin, Mo Mo4 
Rischin, Danny1 
1 Peter MacCallum Cancer Centre, Melbourne, VIC, Australia 2 Prin-
cess Alexandra Hospital, Brisbane, QLD, Australia 3 Austin Hospital, 
Melbourne, VIC, Australia 4 Sydney Cancer Centre, Sydney, NSW, 
Australia 
Background: Concomitant chemoradiation is the treatment of choice 
for locally advanced non small cell lung cancer (NSCLC). The EGF re-
ceptor is activated after radiation and may be implicated in tumour cell 
repopulation. Geﬁtinib (“Iressa”) enhances tumour radioresponsive-
ness in pre-clinical studies. These observations provide a rationale for 
combining geﬁtinib and chemoradiation. This study was undertaken to 
establish the maximum tolerated dose of the combination, and its effect 
on response and survival in NSCLC. 
Methods: Patients with a histologic diagnosis of NSCLC stage III 
disease (no pleural effusion or cervical lymphadenopathy), ECOG 
performance status 0/1, weight loss less than 10%, and no prior treat-
ment were eligible. Patients received radiotherapy 60Gy in 30 fractions 
over six weeks to the primary site and involved lymph nodes. Concur-
rent oral geﬁtinib 250mg per day and carboplatin AUC2 weekly were 
administered with radiotherapy on dose level 1 and weekly paclitaxel 
was added at 25, 35 and 45mg/m2 at dose levels 2, 3 and 4 (expanded 
cohort). The ﬁrst six patients continued geﬁtinib after chemoradiation 
however the protocol was amended to cease geﬁtinib at the end of 
chemoradiotherapy following reports of interstitial lung disease.
